The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.
FTC wants more information on Novo-Catalent deal in antitrust review https://t.co/OVgujnJEAj
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. https://t.co/WaaDXofM4B
US FTC seeks more information on Novo Nordisk parent-Catalent deal https://t.co/gPTYCIuwWU https://t.co/vrJv5qDkHy
FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal https://t.co/gMPWspUKzm
⚠️ US FTC SEEKS MORE INFORMATION ON NOVO NORDISK PARENT-CATALENT DEAL Full Story → https://t.co/MTXKkeiHty The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent. https://t.co/q6227Ie4zX
🚨NEW🚨Novo-Catalent deal is hit with second request from the FTC, as was widely expected. Lots of other pharma groups and contract manufacturers are pushing back against this deal. https://t.co/ZaOnj3BvWt